Peer Review History

Original SubmissionFebruary 5, 2020
Decision Letter - Frank T. Spradley, Editor
Transfer Alert

This paper was transferred from another journal. As a result, its full editorial history (including decision letters, peer reviews and author responses) may not be present.

PONE-D-20-03397

Changing risk factors for placental abruption: a case crossover study using routinely collected data from Finland, Malta and Aberdeen

PLOS ONE

Dear Dr Bhattacharya,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses ALL the points raised during the review process.

SPECIFIC ACADEMIC EDITOR COMMENTS: Your manuscript was reviewed by two experts in the field. Although interest was found in your study, there were several major comments and questions that arose during the review process. These include, but are not limited to the need to clarify the novelty of this specific study, because the majority of these findings are already known. Furthermore, there were requests for additional data about birth weight, IUGR, week of delivery, mode of delivery, patients with induced labor, and specifics about IVF treatment and alcohol use. And the question was raised about how placental abruption was diagnosed in the cases of placenta previa.

We would appreciate receiving your revised manuscript by Apr 18 2020 11:59PM. When you are ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled 'Response to Reviewers'.
  • A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled 'Revised Manuscript with Track Changes'.
  • An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled 'Manuscript'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Frank T. Spradley

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements:

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at http://www.plosone.org/attachments/PLOSOne_formatting_sample_main_body.pdf and http://www.plosone.org/attachments/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For information on unacceptable data access restrictions, please see http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions.

In your revised cover letter, please address the following prompts:

a) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially identifying or sensitive patient information) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.

b) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. Please see http://www.bmj.com/content/340/bmj.c181.long for guidelines on how to de-identify and prepare clinical data for publication. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories.

We will update your Data Availability statement on your behalf to reflect the information you provide.

3. Thank you for stating the following financial disclosure: "No"

a)    Please provide an amended Funding Statement that declares *all* the funding or sources of support received during this specific study (whether external or internal to your organization) as detailed online in our guide for authors at http://journals.plos.org/plosone/s/submit-now.  

b)    Please state what role the funders took in the study.  If any authors received a salary from any of your funders, please state which authors and which funder. If the funders had no role, please state: "The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript."

Please include your amended statements within your cover letter; we will change the online submission form on your behalf.

4. Thank you for stating the following in your Competing Interests section:  "No"

Please complete your Competing Interests on the online submission form to state any Competing Interests. If you have no competing interests, please state "The authors have declared that no competing interests exist.", as detailed online in our guide for authors at http://journals.plos.org/plosone/s/submit-now

 This information should be included in your cover letter; we will change the online submission form on your behalf.

Please know it is PLOS ONE policy for corresponding authors to declare, on behalf of all authors, all potential competing interests for the purposes of transparency. PLOS defines a competing interest as anything that interferes with, or could reasonably be perceived as interfering with, the full and objective presentation, peer review, editorial decision-making, or publication of research or non-research articles submitted to one of the journals. Competing interests can be financial or non-financial, professional, or personal. Competing interests can arise in relationship to an organization or another person. Please follow this link to our website for more details on competing interests: http://journals.plos.org/plosone/s/competing-interests

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: No

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Changing risk factors for placental abruption: a case crossover study using routinely collected data from Finland, Malta and Aberdeen.

This study is a case-crossover study design with records of the two first pregnancies from women who had PA in one pregnancy and not the other.

Cases were pregnancies with abruption and matched controls were pregnancies without abruption in the same woman. A total of 2991 women were included in their study.

The study is well written, and I command the authors for the study design and size of the cohort.

However, I have concerns about the importance and novelty of the data since all risk factors statistically significant in the study are well known in the literature.

Furthermore, in my opinion, some important data is lacking which could influence the results and for example: *Week of delivery, Induction of labor

*Mode of delivery- mainly important in the second pregnancy after PA. Since previous PA is a strong and well known it is possible that an elective Cesarean delivery was performed in an earlier week and affected the occurrence of PA in the coming pregnancy. I ask the authors to add this data if possible.

* IVF treatment and alcohol use- As the authors mentioned in the limitations of the study.

Regarding placenta previa as a risk factor for placenta abruption, how was the diagnosis of abruption done in the cases of placenta previa? Since bleeding is a common symptom did data regarding placenta pathology is present in the registry?

Reviewer #2: I really enjoyed reading your paper. It is refreshing, well designed and well written. I have some minor comments:

1. Is it any reason that you did not include birth weight or more specifically intrauterine growth restriction (IUGR) in your data?

2. Could you please provide the numbers and percentages in your tables as well as OR, CI and P-values?

3. I think you should categorize maternal age into only 3 categories: <20, 20-35 and >35. This is only a suggestion; you don’t have to do that.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: Yes: Elham Baghestan

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files to be viewed.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at figures@plos.org. Please note that Supporting Information files do not need this step.

Revision 1

Reviewer #1:

This study is a case-crossover study design with records of the two first pregnancies from women who had PA in one pregnancy and not the other. Cases were pregnancies with abruption and matched controls were pregnancies without abruption in the same woman. A total of 2991 women were included in their study. The study is well written, and I command the authors for the study design and size of the cohort.

We thank the reviewer for their supportive comments.

However, I have concerns about the importance and novelty of the data since all risk factors statistically significant in the study are well known in the literature.

The aim of the study was to look at the effect of changing some of the already known risk factors on the occurrence of placental abruption keeping the woman-based factors (eg. Genetic predisposition) constant. In fact our starting point was to identify the risk factors implicated in the literature for abruption and see what difference any change in these would make. The novelty of this analysis lies in studying the change in these risk factors and not the risk factors per se. We have added a few sentences in the discussion to reflect this.

Furthermore, in my opinion, some important data is lacking which could influence the results and for example: *Week of delivery, Induction of labor,*Mode of delivery- mainly important in the second pregnancy after PA. Since previous PA is a strong and well known it is possible that an elective Cesarean delivery was performed in an earlier week and affected the occurrence of PA in the coming pregnancy. I ask the authors to add this data if possible; * IVF treatment and alcohol use- As the authors mentioned in the limitations of the study.

Thank you for these suggestions. As we were studying the risk factors preceding placental abruption we did not include the outcomes of pregnancies affected by abruption. We have these outcome data available apart from induction of labour which has a lot of missing data and have added these in additional supplementary tables in the manuscript. We did not have data relating to IVF treatment and alcohol use in all the constituting datasets and have already mentioned this as a weakness in the discussion.

Regarding placenta previa as a risk factor for placenta abruption, how was the diagnosis of abruption done in the cases of placenta previa? Since bleeding is a common symptom did data regarding placenta pathology is present in the registry?

We looked into this further and found that this was driven by the way data was collected in the Finnish birth registry. In the Medical Birth Register in Finland there are two check boxes, and the birth hospitals report these diagnoses at the same time: Placenta previa; only if diagnosed during delivery and Ablatio placentae (premature detachment of placenta). We looked at the overlap in these diagnoses and on average 5 -6 cases were diagnosed as both in each year of delivery. Thus although the absolute numbers were small, the relative risk was high.

Reviewer #2: I really enjoyed reading your paper. It is refreshing, well designed and well written.

Many thanks for the supportive comments.

I have some minor comments:

1. Is it any reason that you did not include birth weight or more specifically intrauterine growth restriction (IUGR) in your data?

As stated earlier, we were interested in looking at the risk factors for placental abruption and not the outcomes of the pregnancy and therefore did not include birthweight or IUGR in the manuscript. We have now included supplementary tables with the outcomes of pregnancy.

2. Could you please provide the numbers and percentages in your tables as well as OR, CI and P-values?

Thank you for this suggestion and we apologise for this oversight. This has now been included.

3. I think you should categorize maternal age into only 3 categories: <20, 20-35 and >35. This is only a suggestion; you don’t have to do that.

Many thanks for this suggestion but we thought there would be more granularity in the data if we categorised maternal age into smaller categories and the relatively large combined dataset allowed us to do so.

Editorial comment:

If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially identifying or sensitive patient information) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.

The dataset was created from three population based international datasets and permissions obtained from governing committees for the 3 databases. Therefore permission for public access to data will need to be given by all three committees. The Finnish register data have been given for this specific study, and the data cannot be shared without authorization from the register keepers. More information on the authorization application to researchers who meet the criteria for access to confidential data can be found at

https://thl.fi/fi/web/thlfi-en/statistics/information-for-researchers/authorisation-application (THL).

Similarly data from Aberdeen can be accessed by applying to the AMND steering committee found at https://www.abdn.ac.uk/iahs/research/obsgynae/amnd/access.php

The data will be deposited in a University of Aberdeen repository after the manuscript is accepted for publication.

Attachments
Attachment
Submitted filename: Response to Reviewers.docx
Decision Letter - Frank T. Spradley, Editor

Changing risk factors for placental abruption: a case crossover study using routinely collected data from Finland, Malta and Aberdeen

PONE-D-20-03397R1

Dear Dr. Bhattacharya,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at https://www.editorialmanager.com/pone/, click the "Update My Information" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

With kind regards,

Frank T. Spradley

Academic Editor

PLOS ONE

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #2: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #2: The autors have responded adequately to my comments. I have no further comments and wish you luck with the publication.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #2: Yes: Elham Baghestan

Formally Accepted
Acceptance Letter - Frank T. Spradley, Editor

PONE-D-20-03397R1

Changing risk factors for placental abruption: a case crossover study using routinely collected data from Finland, Malta and Aberdeen

Dear Dr. Bhattacharya:

I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

For any other questions or concerns, please email plosone@plos.org.

Thank you for submitting your work to PLOS ONE.

With kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Frank T. Spradley

Academic Editor

PLOS ONE

Open letter on the publication of peer review reports

PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.

We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.

Learn more at ASAPbio .